Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Invasive fungal infection is associated with substantial morbidity and mortality in preterm infants. We evaluated the efficacy of prophylactic fluconazole in preventing fungal colonization and invasive infection in extremely-low-birth-weight infants. METHODS: We conducted a prospective, randomized, double-blind clinical trial over a 30-month period in 100 preterm infants with birth weights of less than 1000 g. The infants were randomly assigned during the first five days of life to receive either intravenous fluconazole or placebo for six weeks. We obtained weekly surveillance cultures from all patients. RESULTS: The 50 infants randomly assigned to fluconazole and the 50 control infants were similar in terms of birth weight, gestational age at birth, and base-line risk factors for fungal infection. During the six-week treatment period, fungal colonization was documented in 30 infants in the placebo group (60 percent) and 11 infants in the fluconazole group (22 percent; difference in risk, 0.38; 95 percent confidence interval, 0.18 to 0.56; P=0.002). Invasive fungal infection with positive growth of fungal isolates from the blood, urine, or cerebrospinal fluid developed in 10 infants in the placebo group (20 percent) and none of the infants in the fluconazole group (difference in risk, 0.20; 95 percent confidence interval, 0.04 to 0.36; P=0.008). The sensitivities of the fungal isolates to fluconazole did not change during the study, and no adverse effects of the fluconazole therapy were documented. CONCLUSIONS: Prophylactic administration of fluconazole during the first six weeks of life is effective in preventing fungal colonization and invasive fungal infection in infants with birth weights of less than 1000 g.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, antifungal prophylaxis is now routinely used for extremely premature newborns in some neonatal units and for patients with certain types of hematologic malignancies, dramatically reducing rates of candidemia in these populations (15,16).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [16]
In the citing paper
“The high incidence of candidemia among infants, as well as the significant difference by race in this age group, was noted in the study of Kao et al. (16) and is known to be an important public health problem in this population (17, 35, 42).”
In the citing paper
“reduced the rate of invasive can-didiasis from 20% to 0% ( ) [344].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [344]
In the citing paper
“Regarding the latter observation, it is noteworthy that the formation of biofilms on central venous catheters by Candida spp. is associated with nosocomial infections (121, 122).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [121]
In the citing paper
“C. parapsilosis is notorious for the ability to form biofilms on catheters and other implanted devices (26, 38, 56, 80, 121, 122, 129, 269), for nosocomial spread by hand carriage, and for persistence in the hospital environment (38, 80, 122, 129, 262).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [121]
Citations
Cites
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Hennekens, C. H., Buring, J. E., & Mayrent, S. L. (1987) · Medical Entomology and Zoology · Cited by 2,319
Manual of Clinical Microbiology, 7th ed.
Balows, A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00102-9 · Cited by 1,613
Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v · Cited by 1,360
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Manual of clinical microbiology
Murray, P. R., Versalovic, J. A., & Jorgensen, J. H. (1999) · Cited by 880
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Stoll, B. J., Gordon, T., Korones, S. B., Shankaran, S., Tyson, J. E., Bauer, C. R., Fanaroff, A. A., Lemons, J. A., Donovan, E. F., Oh, W., et al. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70191-9 · Cited by 873
Slavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D., & Bowden, R. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1545 · Cited by 820
Research works printed but not linked: 2
- Spicer AD, 1992, Med Microbiol Lett, 1, 284
- 10.1111/j.1574-6968.2000.tb08938.x · doi:10.1111/j.1574-6968.2000.tb08938.x · Paper page
Cited by
Items 201–300 of 518
Fluconazole Pharmacokinetics and Safety in Premature Infants
Turner, K. C., Manzoni, P., Benjamin, D. K., Cohen‐Wolkowiez, M., Smith, P. B., & Laughon, M. M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803306367 · Cited by 30
“Five randomized control trials, consisting of 726 premature infants, evaluated fluconazole’s effect on hepatotoxicity [33-37].”
BackgroundBalancing the Use of Medications While Maintaining Breastfeeding
Datta, P., Baker, T. E., & Hale, T. W. (2019) · Clinics in Perinatology · doi:10.1016/j.clp.2019.02.007 · Cited by 27
Fungal prophylaxis in very low birth weight neonates: nystatin, fluconazole or nothing?
Isaacs, D. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f8adab · Cited by 27
Arrieta, A. C., Shea, K., Dhar, V., Cleary, J. P., Kukreja, S., Morris, M., Vargas-Shiraishi, O. M., Ashouri, N., & Singh, J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.016 · Cited by 26
Clinical Pharmacology of Anti-Infective Drugs
Wade, K. C., & Benjamin, D. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00037-7 · Cited by 32
Arsenault, A. B., Gunsalus, K. T. W., Laforce‐Nesbitt, S. S., Przystac, L., DeAngelis, E. J., Hurley, M. E., Vorel, E. S., Tucker, R. J., Matthan, N. R., Lichtenstein, A. H., et al. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002042 · Cited by 27
Risk factors associated with candidaemia in the neonatal intensive care unit: a case–control study
Linder, N., Levit-Mor, O., Klinger, G., Kogan, I., Levy, I., Shalit, I., Ashkenazi, S., & Sirota, L. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.04.010 · Cited by 29
Gonia, S., Archambault, L. S., Shevik, M. E., Altendahl, M., Fellows, E., Bliss, J. M., Wheeler, R. T., & Gale, C. A. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00054 · Cited by 26
“Administration of prophylactic doses of fluconazole to infants has been shown to decrease Candida colonization of the intestinal tract as well as the incidence of invasive candidiasis in premature infants (9).”
BackgroundKaufman, D. A., Morris, A., Gurka, M. J., Kapik, B. M., & Hetherington, S. (2014) · Early Human Development · doi:10.1016/s0378-3782(14)70026-x · Cited by 25
“Rates also vary by definition and missing Candida UTIs data would increase overall incidence by 3–4% in preterm infants <1000 g [1,22].”
BackgroundSelf-citationPammi, M., Eddama, O., & Weisman, L. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006068.pub3 · Cited by 26
Young, G. R., Gast, C., Smith, D., Berrington, J. E., Embleton, N. D., & Lanyon, C. V. (2019) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002549 · Cited by 28
“Fluconazole is a triazole antifungal agent routinely orally delivered in this NICU for prophylactic prevention of candidiasis (39).”
BackgroundVendettuoli, V., Tana, M., Tirone, C., Posteraro, B., Sorda, M. L., Fadda, G., Romagnoli, C., & Vento, G. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31817fce78 · Cited by 25
Management ofCandidainfections in the adult intensive care unit
Cruciani, M., & Serpelloni, G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.175 · Cited by 33
“Based on the available evidence, prophylaxis of Candida infection has been found unequivocally effective in preterm infants with birth weights < 1000 or < 1500 g [61,95,105] and in a selected subset of adult patients in the surgical ICU ( Table 3 ).”
BackgroundVázquez, J. A., & Sobel, J. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_11 · Cited by 37
RESISTANT CANDIDA PARAPSILOSIS ASSOCIATED WITH LONG TERM FLUCONAZOLE PROPHYLAXIS IN AN ANIMAL MODEL
Yoder, B. A., Sutton, D. A., Winter, V. T., & Coalson, J. J. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000128777.22022.47 · Cited by 25
Impact of Fluconazole Prophylaxis on Cortisol Levels in Critically Ill Surgical Patients
Magill, S. S., Puthanakit, T., Swoboda, S. M., Carson, K. A., Salvatori, R., Lipsett, P. A., & Hendrix, C. W. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2471-2476.2004 · Cited by 27
“Prophylaxis with fluconazole has been shown to reduce the occurrence of candidiasis in a variety of patient populations (15, 17, 39, 48), including select, high-risk, adult ICU patients (11, 13, 31).”
BackgroundRole of probiotics in prevention of Candida infection in critically ill children
Kumar, S., & Singhi, S. C. (2012) · Mycoses · doi:10.1111/myc.12021 · Cited by 28
Manzoni, P., Mostert, M., Latino, M. A., Pugni, L., Stolfi, I., Decembrino, L., Vagnarelli, F., Corona, G., Tridapalli, E., Vetrano, G., et al. (2012) · Early Human Development · doi:10.1016/s0378-3782(12)70017-8 · Cited by 24
Kirpal, H., Gathwala, G., Chaudhary, U., & Sharma, D. K. (2015) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2015.1013933 · Cited by 24
The use of fluconazole in neonatal intensive care units
Manzoni, P., Mostert, M., Jacqz-Aigrain, É., & Farina, D. (2009) · Archives of Disease in Childhood · doi:10.1136/adc.2008.154385 · Cited by 27
The Use of Antifungal Therapy in Neonatal Intensive Care
Testoni, D., Smith, P. B., & Benjamin, D. K. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2011.12.008 · Cited by 24
Invasive fungal infections during the neonatal period: diagnosis, treatment and prophylaxis
Tezer, H., Canpolat, F. E., & Dilmen, U. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.647685 · Cited by 25
“Studies have shown that preterm infants weighing < 1000 g at birth are at a higher risk for candidemia and fungal-associated mortality than those infants with birth weights of 1000 -- 1500 g [3,13,102].”
BackgroundKaufman, D. A. (2008) · PEDIATRICS · doi:10.1542/peds.2008-1837 · Cited by 24
Self-citationEfficacy of micafungin in treating four premature infants with candidiasis
Kawaguchi, C., Arai, I., Yasuhara, H., Reiko, S. A. N. O., Nishikubo, T., & Takahashi, Y. (2008) · Pediatrics International · doi:10.1111/j.1442-200x.2008.02726.x · Cited by 23
Fluconazole prophylaxis for prevention of invasive candidiasis in infants
Ericson, J. E., & Benjamin, D. K. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000060 · Cited by 23
“This limited total fluconazole exposure to a median of eight doses per infant compared with more than 20 doses per infant used in dosing regimens that treated all VLBW infants for 4–6 weeks [5,7,16].”
BackgroundResultInfluentialRisk factors and prevention for surgical intestinal disorders in extremely low birth weight infants
Yamoto, M., Nakazawa, Y., Fukumoto, K., Miyake, H., Nakajima, H., Sekioka, A., Nomura, A., Ooyama, K., Yamada, Y., Nogami, K., et al. (2016) · Pediatric Surgery International · doi:10.1007/s00383-016-3940-z · Cited by 23
Healthcare-Associated Infections in the Neonate
Sass, L. A., & Karlowicz, M. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00094-3 · Cited by 28
“20%, respectively), but the level of invasive candidiasis was higher in their NICU than in centers in the NICHD NRN at that time.(145) The strongest effect appears to occur when prophylaxis is targeted to high-risk patients with birth weights of less than 1000 g and with use of CVCs.”
BackgroundEarly-onset neutropenia is a risk factor for Candida colonization in very low-birth-weight neonates
Manzoni, P., Farina, D., Monetti, C., Priolo, C., Leonessa, M., Giovannozzi, C., & Gomirato, G. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.10.018 · Cited by 24
Lumbreras, C., Lizasoaín, M., & Aguado, J. M. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72964-4 · Cited by 45
“Muy recientemente, un estudio aleatorizado, controlado con placebo, ha demostrado que la administración de fluconazol en niños prematuros de muy bajo peso es capaz de reducir la incidencia de infección profunda por Candida 32 .”
BackgroundSerum 1,3-βD-Glucan Assay in the Diagnosis of Invasive Fungal Disease in Neonates
Mackay, C. A., Ballot, D. E., & Perovic, O. (2011) · Pediatric Reports · doi:10.4081/pr.2011.e14 · Cited by 22
Scott, B. L., Hornik, C. D., & Zimmerman, K. O. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1773793 · Cited by 26
Prophylaxis of Invasive Fungal Infection in Neonates: A Narrative Review for Practical Purposes
Ferrando, G., & Castagnola, E. (2023) · Journal of Fungi · doi:10.3390/jof9020164 · Cited by 25
Clinical pharmacology of antifungal agents in pediatric patients
Chiou, C. C., Walsh, T. J., & Groll, A. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2465 · Cited by 25
“Fluconazole has been shown to reduce Candida infections in low birth-weight infants [103-108] .”
BackgroundAntifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis
Autmizguine, J., Tan, S., Cohen‐Wolkowiez, M., Cotten, C. M., Wiederhold, N. P., Goldberg, R. N., Adams-Chapman, I. S., Stoll, B. J., Smith, P. B., & Benjamin, D. K. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001913 · Cited by 22
Anaraki, M. R., Nouri‐Vaskeh, M., & Oskouie, S. A. (2020) · Korean Journal of Pediatrics · doi:10.3345/cep.2019.01431 · Cited by 22
Martin, A., Pappas, A., Lulic‐Botica, M., & Natarajan, G. (2011) · Journal of Perinatology · doi:10.1038/jp.2011.27 · Cited by 22
Participation of the ABC Transporter CDR1 in Azole Resistance of Candida lusitaniae
Borgeat, V., Brandalise, D., Grenouillet, F., & Sanglard, D. (2021) · Journal of Fungi · doi:10.3390/jof7090760 · Cited by 24
“Intravenously, fluconazole prophylaxis was a standard protocol in the NICU for premature infants with a birth weight of less than 1000 g, or a gestational age of less than 28 weeks, in agreement with international guidelines [13,14].”
ResultPacora, P., Romero, R. J., Erez, O., Maymon, E., Panaitescu, B., Kusanovic, J. P., Tarca, A. L., Hsu, C., & Hassan, S. S. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1416083 · Cited by 23
Kourti, M., & Roilides, E. (2022) · Pathogens · doi:10.3390/pathogens11020242 · Cited by 20
“As triazole derivatives became widely available, the incidence of ITI decreased in early the 2000s [16] followed by a re-emergence of Trichosporon as an increasingly common pathogen in immunocompromised”
BackgroundNew possibilities of prevention of infection in the newborn
Borghesi, A., Tzialla, C., Decembrino, L., Manzoni, P., & Stronati, M. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.604934 · Cited by 20
“In a randomized, double-blinded clinical trial by Kaufman et al [9]., prophylactic intravenous fluconazole was administered at the dose of 3 mg/kg every 3 days for the first 2 weeks of life, every 2 days during the third and fourth week of life, and every day during the fifth and sixth week of life in ELBW neonates at…”
BackgroundPattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit
Girardi, A. M., Galletti, S., Raschi, E., Koci, A., Poluzzi, E., Faldella, G., & Ponti, F. D. (2017) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-017-0354-z · Cited by 20
Advances in the Treatment of Mycoses in Pediatric Patients
Iosifidis, Ε., Papachristou, S., & Roilides, E. (2018) · Journal of Fungi · doi:10.3390/jof4040115 · Cited by 20
Fanos, V., Antonucci, R., Zaffanello, M., & Mussap, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803306439 · Cited by 20
“Among azoles, fluconazole is by far the most widely used and has been reported to be relatively well tolerated, even at renal level [81-85].”
BackgroundCandidiasis invasoras en recién nacidos: diagnóstico, tratamiento y prevención
Giannina Izquierdo, C., & Santolaya, M. E. (2014) · Revista chilena de infectología · doi:10.4067/s0716-10182014000100011 · Cited by 22
Fluconazole use and safety in the nursery
Castagnola, E., Jacqz-Aigrain, É., Kaguelidou, F., Maragliano, R., Stronati, M., Rizzollo, S., Farina, D., & Manzoni, P. (2012) · Early Human Development · doi:10.1016/s0378-3782(12)70005-1 · Cited by 19
“However, while the median duration of fluconazole administration in the most representative clinical trials was about 45 days [19,25], in other paediatric populations such as allogenic haematopoietic stem-cell transplant recipients the use of fluconazole has been recommended for longer periods and at dosages higher th…”
BackgroundA Murine Model for Disseminated Candidiasis in Neonates
Tsai, N. Y., Laforce‐Nesbitt, S. S., Tucker, R. J., & Bliss, J. M. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e318206fd3e · Cited by 23
Rundjan, L., Wahyuningsih, R., Oeswadi, C. A., Marsogi, M., & Purnamasari, A. (2020) · BMC Pediatrics · doi:10.1186/s12887-020-02074-0 · Cited by 19
Leibovitz, E., Livshiz‐Riven, I., Borer, A., Taraboulos-Klein, T., Zamir, O., Shany, E., Melamed, R., Flidel‐Rimon, O., Bradenstein, R., Chodick, G., et al. (2013) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2013.814150 · Cited by 21
Rueda, K., Moreno, M. T., Espinosa, M., & Sáez‐Llorens, X. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181e9dea2 · Cited by 19
Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update
Pana, Z. D., Kougia, V., & Roilides, E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1013936 · Cited by 19
“reported a significant decrease in the incidence of IC in infants < 1000 g with the use of fluconazole (0 vs 20% in the control group) without the emergence of fluconazole-resistant fungal species [14].”
BackgroundRecommendations for the management of candidemia in neonates in Latin America
Santolaya, M. E., Matute, T. A., Telles, F. D. Q., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.012 · Cited by 30
Zhao, W., Guellec, C. B., Benjamin, D. K., Hope, W. W., Bourgeois, T., Watt, K., van den Anker, J. N., Matrot, B., Saxén, H., Hoppu, K., et al. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0169-7 · Cited by 18
“Fluconazole has been used for many years to prevent or treat neonatal candidiasis in an off-label manner [7, 8].”
Care of the Extremely Low-Birthweight Infant
Eichenwald, E. C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0134-0.10032-0 · Cited by 18
Dignani, M. C., Solomkin, J. S., & Anaissie, E. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00008-6 · Cited by 34
Leather, H. L., & Wingard, J. R. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200208000-00003 · Cited by 18
Ericson, J. E., Agthe, A. G., & Weitkamp, J.-H. (2024) · Clinics in Perinatology · doi:10.1016/j.clp.2024.10.003 · Cited by 17
Fluconazole Prophylaxis in High-Risk Neonates
Reed, B. N., Caudle, K. E., & Rogers, P. D. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m364 · Cited by 20
Cost Analysis of Fluconazole Prophylaxis for Prevention of Neonatal Invasive Candidiasis
Swanson, J. R., Vergales, J., Kaufman, D. A., & Sinkin, R. A. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001068 · Cited by 18
Self-citationXie, J., Zhu, L., Zhu, T., Jian, Y., Ding, Y., Zhou, M., & Feng, X. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-74 · Cited by 20
Luparia, M., Landi, F., Mesini, A., Militello, M. A., Galletto, P., Farina, D., Castagnola, E., & Manzoni, P. (2019) · American Journal of Perinatology · doi:10.1055/s-0039-1691808 · Cited by 17
Fluconazole prophylaxis in preterm infants: a systematic review
Rios, J. F. D. S., Camargos, P. A. M., Corrêa, L. P., & Romanelli, R. M. D. C. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.01.008 · Cited by 22
Controversies about the management of invasive fungal infections in very low birth weight infants
Moreira, M. E. L. (2005) · Jornal de Pediatria · doi:10.1590/s0021-75572005000200007 · Cited by 18
Antifungal prophylaxis for the prevention of neonatal candidiasis?
O'Grady, M. J., & Dempsey, E. M. (2008) · Acta Paediatrica · doi:10.1111/j.1651-2227.2008.00687.x · Cited by 17
“A single-centre randomized double-blind trial demonstrated that fluconazole prophylaxis during the first 42 days of life reduced both colonization and invasive infection in a population of ELBW infants with endotracheal tubes or central vascular catheters (7).”
BackgroundNosanchuk, J. D. (2002) · Frontiers in bioscience · doi:10.2741/a850 · Cited by 16
Auriti, C., Rose, D. U. D., Santisi, A., Martini, L., Ronchetti, M. P., Ravà, L., Antenucci, V., Bernaschi, P., Serafini, L., Catarzi, S., et al. (2022) · Journal of Hospital Infection · doi:10.1016/j.jhin.2022.09.018 · Cited by 15
Twice‐weekly fluconazole prophylaxis in premature infants: Association with cholestasis
Bhat, V., Fojas, M., Saslow, J. G., Shah, S. H., Sannoh, S. E., Amendolia, B., Pyon, K. H., Kemble, N., Stahl, G. E., & Aghai, Z. H. (2010) · Pediatrics International · doi:10.1111/j.1442-200x.2010.03286.x · Cited by 16
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 26
“En 2 estudios recientes, la incidencia de candidiasis en las ramas del placebo fueron del 20% en recién nacidos de menos de 1000 g de peso y del 13% en recién nacidos entre 1000 y 1500 g de peso [240, 241].”
BackgroundBuffet‐Bataillon, S., Bellanger, A., Boudry, G., Gangneux, J., Yverneau, M., Beuchée, A., Blat, S., & Huërou‐Luron, I. L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.676622 · Cited by 19
“A multitude of animal studies have shown that SCFAs widespreadly may be involved in critical phases of neurodevelopmental and neurodegenerative disorders (Sharon et al., 2016; Dinan and Cryan, 2017; Fung et al., 2017; Kelly et al., 2017; Dalile et al., 2019).”
BackgroundGarber, S. J., & Puopolo, K. M. (2015) · NeoReviews · doi:10.1542/neo.16-4-e211 · Cited by 15
Oral amphotericin B for the prevention of Candida bloodstream infection in critically ill children*
Ben‐Ari, J., Samra, Z., Nahum, E., Levy, I., Ashkenazi, S., & Schonfeld, T. M. (2006) · Pediatric Critical Care Medicine · doi:10.1097/01.pcc.0000200946.30263.b6 · Cited by 15
“Prophylactic administration of fluconazole to very-low-birthweight infants resulted in decreased risk of colonization and invasive fungal infection (14, 15).”
BackgroundEffects of cessation of a policy of neonatal fluconazole prophylaxis on fungal resurgence.
Dutta, S., Murki, S., Varma, S., Narang, A., & Chakrabarti, A. (2005) · PubMed · Cited by 15
Agrawal, S., Rao, S. C., & Patole, S. (2015) · Mycoses · doi:10.1111/myc.12368 · Cited by 16
Infection and Inflammation of the Pediatric Genitourinary Tract
Shortliffe, L. M. D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00116-x · Cited by 18
Seasonality of invasive Candida infection in neonates
Edi-Osagie, N. E., & Emmerson, A. J. B. (2004) · Acta Paediatrica · doi:10.1080/08035250410022341 · Cited by 15
Fluconazole Prophylaxis in the Neonatal Intensive Care Unit
Healy, C. M., & Baker, C. J. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819693ac · Cited by 15
Antifungal Agents and Fungal Prophylaxis in the Neonate
Kicklighter, S. D. (2002) · NeoReviews · doi:10.1542/neo.3-12-e249 · Cited by 17
Skin Surface pH in Newborns: Origin and Consequences
Fluhr, J. W., & Darlenski, R. (2018) · Current problems in dermatology · doi:10.1159/000489515 · Cited by 16
HealthCare–Associated Infections in the Nursery
Coffin, S. E., & Zaoutis, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00035-3 · Cited by 16
Aiming for Zero: Preventing Invasive Candida Infections in Extremely Preterm Infants
Kaufman, D. A. (2011) · NeoReviews · doi:10.1542/neo.12-7-e381 · Cited by 14
Self-citationChe, D., Zhou, H., Li, T., & Wu, B. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1645-5 · Cited by 14
“Kaufman, 2001 [8] ELBW 50 50 42 3 mg/kg every 3 days for weeks 1–2, every 2 days for weeks 3–4, and daily for weeks 5–6 1.”
BackgroundUppuluri, P., Khan, A. A., & Edwards, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_2 · Cited by 18
“Numerous studies examining fluconazole prophylaxis for the prevention of invasive candidiasis in neonates have consistently demonstrated efficacy and possibly reduced mortality (Kaufman et al. 2001; Manzoni et al. 2006, 2007) (for a complete list of these studies refer reference # (Pappas et al.”
BackgroundZhang, L., Yang, L., Dong, W., Liu, X., Lei, X., & Zhang, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-00120-0 · Cited by 14
Chen, J., Yu, X., Zhou, Y., Zhang, Y., Zhu, J., Xie, L., Qian, J., Yang, Q., Xia, H., Zhu, T., et al. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2015.07.011 · Cited by 16
Clinical microbiology of neonatal candidiasis in Hungary
Kristóf, K., Janik, L., Komka, K., Harmath, Á., Hajdú, J., Nobilis, A., Rozgonyi, F., Nagy, K., Rigó, J., & Szabó, D. (2010) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.57.2010.4.7 · Cited by 27
“Some recent report suggests that the treatment can reduce but not eliminate invasive fungal infection [2, 3].”
BackgroundErcan, T. E., Sağlam, Ö., Büyükkale, G., Kavuncuoğlu, S., Mete, F., & Çetınkaya, M. (2014) · American Journal of Perinatology · doi:10.1055/s-0034-1371358 · Cited by 13
Charoo, N. A., Cristofoletti, R., & Dressman, J. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12411 · Cited by 13
Silva-Rios, J., Camargos, P. A. M., Corrêa, L. P., & Romanelli, R. M. D. C. (2019) · Journal of Neonatal-Perinatal Medicine · doi:10.3233/npm-17121 · Cited by 14
“Studies comparing non-prophylaxis group with prophylactic fluconazole groupsfoundnosignificantdifferenceinthisoutcome [20,25,26].”
Pharmacokinetics of Fluconazole in the Cerebrospinal Fluid of Children with Hydrocephalus
Bafeltowska, J. J., & Buszman, E. (2005) · Chemotherapy · doi:10.1159/000088965 · Cited by 13
Chang, Y. J., Choi, I. R., Shin, W. S., Lee, J. H., Kim, Y. K., & Park, M. S. (2013) · Korean Journal of Pediatrics · doi:10.3345/kjp.2013.56.2.68 · Cited by 14
“Systemic steroids 13/57 (23) 7/42 (17) 0.”
Çerikçioğlu, N., İlki, A., Bilgen, H. S., Özek, E., Metin, F., & Kalaça, S. (2004) · PubMed · Cited by 13
Recomendaciones para el manejo de la candidemia en neonatos en América Latina
Santolaya, M. E., Matute, T. A., Telles, F. D. Q., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.002 · Cited by 18
JSMM Clinical Practice Guidelines for Diagnosis and Treatment of Invasive Candidiasis
(2013) · Medical Mycology Journal · doi:10.3314/mmj.54.147 · Cited by 12
O Recém-nascido de Alto Risco: teoria e prática do cuidar
Moreira, M. E. L., Lopes, J. M. D. A., & de Carvalho, M. (2004) · Editora FIOCRUZ eBooks · doi:10.7476/9788575412374 · Cited by 75
Targeted fluconazole prophylaxis for high-risk very low birth weight infants
Rolnitsky, A., Levy, I., Sirota, L., Shalit, I., & Klinger, G. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-012-1760-2 · Cited by 12
“Since the initial study [13] on prophylactic treatment with fluconazole in VLBW infants, several [6, 12, 19, 20] studies have advocated the use of fluconazole as a preventive treatment that has been shown to decrease the rate of invasive fungal infections and possibly decrease mortality.”
ResultEpidemiology and clinical outcome of candidaemia among Jordanian newborns over a 10-year period
Badran, E., Albaramki, J., Shamyleh, A. A., Shehabi, A. A., & Khuri-Bulos, N. A. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701477550 · Cited by 12
“Other studies demonstrated the usefulness of fluconazole prophylaxis during the first 6 weeks of life in extremely low birth weight infants (birth weight B1000 g) with central vascular catheters or intubation to decrease fungal colonization and invasive disease [25].”
BackgroundMixed Infection with Unusual fungi and Staphylococcal Species in Two Extremely Premature Neonates
Maheshwari, A., Stromquist, C. I., Pereda, L., & Emmanuel, P. J. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211077 · Cited by 12
“Invasive fungal infections continue to be associated with substantial morbidity and mortality in preterm infants.(1) We report two extremely low-birth-weight (ELBW) infants who had a mixed infection with Staphylococcal species and unusual fungal pathogens.”
BackgroundPrevention of invasiveCandidainfections in preterm infants: the time is now
Kaufman, D. A. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.4.393 · Cited by 14
Self-citationManzoni, P., Farina, D., d’Oulx, E. A., Leonessa, M., Gomirato, G., & Arisio, R. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.07.008 · Cited by 12
Xie, J., Zeng, J., & Zheng, S. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-023-01460-5 · Cited by 11
“[8] 2001 50/50 744 ± 157/ 717 ± 150 3 mg/kg, every third day for two weeks;”
Epidemiology of Systemic Fungal Diseases: An Overview
Park, B. J., Chiller, T. M., Brandt, M. E., & Warnock, D. W. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_2 · Cited by 15
Metadata
- Authors
- Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G.
- Affiliations
- University of Virginia (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-12-06
- Volume
- 345
- Issue
- 23
- Pages
- 1660-1666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2016673581
- Cited by
- 523
- References
- 46
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 13 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 21 · 2018: 17 · 2017: 18 · 2016: 19 · 2015: 18 · 2014: 24 · 2013: 26 · 2012: 42
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- fluconazole, antifungal prophylaxis, preterm infants, extremely low birth weight infants, invasive fungal infections, fungal colonization
- MeSH terms
- Antifungal Agents, Bacterial Infections, Candida, Candida albicans, Candidiasis, Double-Blind Method, Humans, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases, Infusions, Intravenous, Microbial Sensitivity Tests, Mycoses, Prospective Studies, Trichosporon, Colony Count, Microbial, Fluconazole, Infant, Very Low Birth Weight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.